Lineage Cell Therapeutics Inc. has withdrawn its application for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine (CIRM), which was intended to support the continued clinical development of OPC1 for spinal cord injuries. The withdrawal followed feedback from CIRM, though no specific deficiencies were identified in the application. The company plans to address the feedback and submit a revised application in the next CIRM grant cycle, scheduled for January 2026. The withdrawal and planned resubmission do not affect the ongoing or planned development of OPC1 or the DOSED clinical study. No other organizations were mentioned as recipients of this grant application.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-302552), on November 28, 2025, and is solely responsible for the information contained therein.